Effect of entacapone on plasma homocysteine levels in Parkinson’s disease patients
- First Online:
- Cite this article as:
- Nevrly, M., Kanovsky, P., Vranova, H. et al. Neurol Sci (2010) 31: 565. doi:10.1007/s10072-010-0262-0
- 122 Downloads
Peripheral metabolism of l-DOPA via enzyme catechol-O-methyltransferase (COMT) is one of the possible sources of homocysteine (HCY). The aim of this study was to assess plasma HCY levels in l-DOPA-treated Parkinson’s disease (PD) patients and its influence by adding the inhibitor COMT (entacapone). Patients were divided into two groups: (1) patients long term treated with l-DOPA but were naïve to entacapone, (2) l-DOPA naïve patients, in whom a combined treatment with l-DOPA and entacapone was started. The HCY levels were higher in Group 1 than in Group 2. No statistically significant changes of HCY concentrations were found in both patient groups after adding entacapone to their l-DOPA treatments. Results of this study confirm that patients treated with l-DOPA for a long term have increased plasma HCY concentrations. We believe combined l-DOPA and entacapone therapy could be a possible protective mechanism against hyperhomocysteinemia in early PD.